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Abstract On the basis of the recently published results of
a clinical trial comparing 12 and 36 months of imatinib in
adjuvant therapy for gastrointestinal stromal tumors
(GISTs), which demonstrated clinical benefit of longer
imatinib treatment in terms of delaying recurrences and
improving overall survival, both the US Food and Drug
Administration and the European Medicines Agency have
updated their recommendations and approved 36 months of
imatinib treatment in patients with v-kit Hardy-Zuckerman
4 feline sarcoma viral oncogene homolog (KIT)-positive
GISTs (also known as CD117-positive GISTs) at high risk
of recurrence after surgical resection of a primary tumor.
This article discusses patient selection criteria for extended
adjuvant therapy with imatinib, different classifications of
risk of recurrence, and assessment of the response to
therapy.
1 Introduction
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal neoplasms of the gastrointestinal
tract, with a mean annual incidence of 10–15 cases per
million people, affecting mainly older individuals at a
median age of 55–65 years [1–4]. Radical surgery is the
treatment of choice in primary resectable GISTs, but
almost all GISTs are associated with a risk of recurrence,
and approximately 40–50 % of patients with potentially
curative resections develop recurrent or metastatic disease
[5, 6]. Classic cytotoxic chemotherapy is ineffective in
advanced cases. Radiotherapy has restricted efficacy in
the management of GISTs, principally because the tumor
location is surrounded by dose-limiting vital organs. The
prognosis of patients with inoperable or metastatic GISTs
was poor until the beginning of the 21st century, when
significant progress in understanding the molecular path-
ogenesis of GISTs resulted in development of a treatment
that has become a model of targeted therapy in oncology.
The introduction of imatinib mesylate (GleevecTM or
Glivec; Novartis), a small-molecule selective inhibitor of
receptor tyrosine kinases, has revolutionized the treatment
of GISTs, both in the adjuvant setting and in advanced
(i.e., inoperable and/or metastatic) cases. On the basis of
recently published results of a clinical trial comparing 12
and 36 months of adjuvant imatinib therapy [7], demon-
strating clinical benefit of longer imatinib treatment in
terms of delaying recurrences and improving overall
survival (OS), both the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) have
updated their recommendations and approved 36 months
of imatinib treatment in patients with v-kit Hardy-Zuck-
erman 4 feline sarcoma viral oncogene homolog (KIT)-
positive GISTs (also known as CD117-positive GISTs) at
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high risk of recurrence after surgical resection of the
primary tumor.
2 Clinical and Molecular Features of GISTs
GISTs may originate anywhere in the gastrointestinal
tract—most frequently in the stomach, followed by the
small intestine. They comprise a heterogeneous group of
tumors ranging from small lesions with clinically benign
behavior to highly aggressive malignant tumors [8–10].
Metastases develop mainly in the liver or intraperitoneally
and may even occur more than 10 years after surgery on
the primary lesion, necessitating long-term follow-up of
GIST patients [9, 11]. GISTs are believed to arise from
progenitors related to the interstitial cells of Cajal, which
are the pacemakers for peristalsis [12–14]. Approximately
85–95 % of GISTs express KIT, which is currently used for
routine immunohistochemical diagnosis [15]. Other well-
established immunohistochemical markers used for differ-
ential diagnosis include DOG1 [Discovered on GIST-1;
encoded by the ANO1 (anoctamin 1, calcium activated
chloride channel) gene], CD34 (a hematopoietic progenitor
stem-cell antigen), smooth muscle actin, S100 protein, and
desmin (a muscle cell marker) [16–21]. Characteristic
genomic alterations in both benign and malignant GISTs
mainly involve chromosomal losses of 1p, 14q, and 22q.
Additional cytogenetic abnormalities present in metastatic
GISTs involve losses of chromosomes 13q, 15q, and 18,
and partial deletions of 11p and 9p [including tumor sup-
pressor genes CDKN2A (cyclin-dependent kinase inhibitor
2A) and CDKN2B], as well as gains of 5p, 8q, and 17q
[22–28].
Approximately 75–80 % of sporadic GISTs harbor KIT-
activating mutations, and another 5–13 % of sporadic
GISTs carry platelet-derived growth factor receptor, alpha
polypeptide (PDGFRA)-activating mutations [29, 30].
About two thirds of all mutations in GISTs occur at the 50
end of KIT exon 11. Less common primary mutation sites
in KIT include the 30 end of exons 11 and 9. The most
frequently mutated region in PDGFRA is exon 18, typically
exhibiting the p.D842V substitution.
Approximately 10–15 % of GISTs do not present
detectable mutations in KIT or PDGFRA [29–40]. KIT/
PDGFRA wild-type GISTs arise mainly from the stomach
and are characterized by distinct clinical and pathological
features, including predominant incidence in young female
patients, epithelioid morphology, frequent lymphovascular
invasion and lymph node metastases, and unpredictable
clinical behavior. Wild-type GISTs carry inactivating
mutations in genes coding for mitochondrial succinate
dehydrogenase (SDH) complex II subunits A, B, C, and D,
which are components of the Krebs cycle and the respira-
tory chain. Additionally, this subgroup of GISTs express
insulin-like growth factor 1 receptor (IGF1R). Wild-type
GISTs are commonly associated with Carney’s triad,
Carney-Stratakis syndrome, or neurofibromatosis type 1
[41–51].
Table 1 Molecular classification of gastrointestinal stromal tumors (GISTs) according to v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog (KIT) and platelet-derived growth factor receptor, alpha polypeptide (PDGFRA) mutational status
Genotype Features
KIT mutations (75–80 % of sporadic GISTs)
Exon 11 Most common mutation in sporadic GISTs (65–70 %); present in tumors localized at all gastrointestinal sites; best
response to imatinib; also reported in familial GISTs
Exon 9 More common in GISTs originating from the small bowel/colon; intermediate/dose-dependent response to imatinib in
advanced GISTs
Exon 13 Present in tumors localized at all gastrointestinal sites; observed clinical responses to imatinib; reported in familial GISTs;
more often as secondary mutations in imatinib-resistant tumors
Exon 17 Present in tumors localized at all gastrointestinal sites; observed clinical responses to imatinib (except for p.D816V);
reported in familial GISTs; more often as secondary mutations in imatinib-resistant tumors
PDGFRA mutations (5–13 % of sporadic GISTs)
Exon 12 Present in tumors localized at all gastrointestinal sites; observed clinical responses to imatinib
Exon 14 Only a few cases described in the literature; more common in GISTs originating from the stomach
Exon 18 More common in GISTs originating from the stomach, usually with epithelioid morphology; often related to indolent




Frequent in pediatric GISTs; poor response to imatinib; typical for GISTs related to neurofibromatosis type 1, Carney’s
triad (gastric GIST ? pulmonary chondroma ± paraganglioma), or Carney-Stratakis syndrome
(GIST ? paraganglioma, characterized by mutations in genes encoding SDH subunits SDHA, SDHB, SDHC, SDHD),
and/or IGF1R expression
IGF1R insulin-like growth factor 1 receptor, SDH succinate dehydrogenase
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Table 1 summarizes the most important molecular fea-
tures of GISTs in terms of KIT and PDGFRA mutational
status.
3 Imatinib Mesylate Therapy for Advanced GISTs
Imatinib mesylate was initially developed for the treatment
of chronic myelogenous leukemia, to specifically inhibit
the tyrosine kinase activity of breakpoint cluster region–
c-abl oncogene 1, non-receptor tyrosine kinase (BCR–ABL)
fusion oncoprotein [52]. However, in preclinical studies, it
was demonstrated that imatinib also inhibited the activity of
KIT, PDGFRA/B, ABL1, and ABL2 (also known as ARG)
tyrosine kinases [53, 54], which encouraged examination of
imatinib therapy for other neoplasms driven by constitutive
receptor tyrosine kinase activation. The first report
describing imatinib treatment in a GIST patient with mul-
tiple metastatic lesions demonstrated a dramatic response to
this therapy [55]. As early as 2002, imatinib was registered
for treatment of advanced GISTs (i.e. in metastatic and/or
recurrent and/or inoperable disease). The results of several
clinical trials confirmed the high efficacy of imatinib in the
treatment of GISTs in the majority of patients with inoper-
able/metastatic disease [56–60], prolonging median survival
from 10–19 months (historical data) to approximately
5 years. Two large, parallel, very similar international
studies comparing a standard imatinib dose of 400 mg daily
with a high dose of 800 mg daily demonstrated a similar
response rate and OS with the two imatinib doses but better
progression-free survival (PFS) in the high-dose treatment
arm [60–62]. Moreover, data from these trials have shown
that the response of GISTs with KIT exon 9 mutations
depends on the dose of the drug, and that these patients
benefit from a higher dose (800 mg daily) of imatinib,
demonstrating significantly longer PFS (18 months) than
patients receiving a standard dose of 400 mg daily
(6 months) [39]. Unfortunately the spectacular activity of
imatinib is time limited, and secondary resistance develops
in the majority of patients [11, 61].
4 Adjuvant Imatinib Mesylate Therapy for GISTs
Although the treatment of choice in primary resectable
localized GISTs is radical resection with negative margins,
almost half of the patients ultimately develop recurrent or
metastatic disease after potentially curative surgery [63].
Therefore, the idea of adjuvant therapy with imatinib after
primary resection has been evoked to delay or prevent
relapse and to prolong patients’ survival. The role of
imatinib therapy in the adjuvant setting has been evaluated
in several phase II and III clinical trials, namely ACOSOG
Z9000 [98] and Z9001 [76] (conducted by the American
College of Surgeons Oncology Group), SSGXVIII/AIO
[7, 65] (conducted by the Scandinavian Sarcoma Group
and the Sarcoma Group of the Arbeitsgemeinschaft Inter-
nistische Onkologie XVIII), RTOG S0132 [95] (conducted
by the Radiation Therapy Oncology Group), and EORTC
62024 (conducted by the European Organization for
Research and Treatment of Cancer) [99]. Table 2 presents
the most important clinical trials of adjuvant imatinib in
GISTs. Data from the phase III ACOSOG Z9001 trial [76]
evaluating 1 year of adjuvant therapy with imatinib
400 mg daily versus placebo in patients after microscopi-
cally radical (R0) resection of GISTs at least 3 cm in
diameter showed a significant reduction in the risk of
recurrence from 17 to 2 % at 1 year (during 20 months of
follow-up) [p = 0.0001], with a hazard ratio (HR) of 0.35.
Although the treatment was well tolerated, no significant
impact on OS was demonstrated, thus implying that adju-
vant imatinib delays rather than prevents relapse. The eli-
gibility criteria for this trial were clearly inadequate
because more than 40 % of patients had tumors between 3
and 6 cm in size, which in the majority were at low risk of
relapse and did not require adjuvant therapy after surgery.
Nevertheless, in 2008, imatinib was approved for use in
adjuvant therapy after resection of primary GISTs in
patients at significant risk of relapse. Importantly, the ini-
tial approval lacked definite guidance concerning the
optimal duration of treatment and risk assessment criteria.
Only recent updates of the European Society for Medi-
cal Oncology (ESMO) and National Comprehensive Can-
cer Network (NCCN) guidelines have included the
recommendation for 36 months of adjuvant imatinib ther-
apy in adult patients with KIT-positive GISTs at high risk
of relapse. However, the optimal duration of imatinib
therapy is still unknown.
The latest FDA and EMA approvals for imatinib were
based on the results of the SSGXVIII/AIO trial, which
demonstrated that prolonged treatment extends both
recurrence-free survival (RFS) and OS [64]. Data from the
SSGXVIII/AIO trial, comparing 12 and 36 months of
adjuvant imatinib treatment after resection of GISTs in
patients with a high risk of recurrence, were first presented
in 2011 at the 47th Annual Meeting of the American
Society of Clinical Oncology. In the 36-month treatment
arm, a significant improvement was observed in terms of
both RFS (5-year RFS: 65.6 vs. 47.9 %; p \ 0.0001) and
OS (5-year OS: 92.0 vs. 81.7 %; p = 0.01; HR 0.45). The
treatment was most effective in patients carrying KIT exon
11 mutations. The study demonstrated that prolonged
imatinib treatment was generally well tolerated, and the
most common adverse events included anemia, leukopenia,
periorbital edema, fatigue, nausea, diarrhea, muscle
cramps, and elevated blood lactate dehydrogenase levels.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12 P. Rutkowski et al.
More patients discontinued imatinib therapy in the
36-month treatment arm than in the 12-month arm, for
reasons other than GIST recurrence (25.8 vs. 12.6 %;
p \ 0.001) [7, 65].
5 Assessment of the Risk of Recurrence after Primary
Surgery, and Patient Selection for Extended
Adjuvant Imatinib Therapy
Evaluation of the risk factors for recurrence after primary
surgery is essential for reliable prognosis, scheduling of
follow-up, and identification of patients who may poten-
tially benefit from adjuvant therapy. The main criteria
taken into account in a few existing risk stratification
systems include the tumor site, size, mitotic index, and
tumor rupture; however, the uniform risk criteria remain
difficult to determine.
The National Institutes of Health (NIH) consensus criteria
formulated in 2001 provided the first evidence-based cate-
gorization and a practical scheme for risk assessment in the
clinical course of this disease. This risk classification was
based on the tumor size and mitotic rate [evaluated per 50
high-powered fields (HPFs)] as the most reliable prognostic
factors [66]. This scheme was complemented in 2006 by
Miettinen and Lasota from the Armed Forces Institute of
Pathology (AFIP), who recognized the significance of the
tumor location as an independent prognostic factor in GISTs.
They created a new risk assessment scheme (recommended
by the NCCN and commonly used) which reflected better
prognosis of gastric GISTs compared with intestinal GISTs
of the same mitotic index and size [21, 67–70] (Table 3 and
Fig. 1). The same prognostic factors were taken into account
in the nomogram created by Gold et al. [71], which seems to
vaguely outperform the NIH and NCCN–AFIP criteria.
Moreover, it has been demonstrated that tumor rupture
(either spontaneous or iatrogenic) is an important risk factor,
which strongly correlates with the risk of recurrence in
GISTs [72, 73]. This observation has led to the development
of modified NIH criteria and novel non-linear risk stratifi-
cation systems, including prognostic contour maps and heat
maps, constructed on the basis of the tumor size, site, mitotic
index, and incidence of tumor rupture [73–75]. These fea-
tures may provide even more accurate estimation of the risk
of recurrence and are appropriate for individualizing risk
stratification for adjuvant therapy in GISTs. Subgroup
analysis of the ACOSOG Z9001 trial confirmed that the
major clinical benefit of adjuvant therapy was limited to
the group of patients at high risk of relapse according to the
NCCN–AFIP criteria (an improvement in 2-year RFS from
41 to 77 %; p \ 0.0001) [76].
In addition to clinicopathological factors, molecular























































































































































































































































































































































































































































































































































































































































Extended Adjuvant Imatinib Therapy for GISTs 13
of GISTs. However, they have not been included in the
present risk assessment guidelines. Several studies have
demonstrated better prognosis for patients harboring KIT
exon 11 point mutations or insertions, as well as PDGFRA
exon 18 mutations. On the other hand, tumors carrying KIT
exon 11 deletions (especially involving codons 557 or 558)
and KIT exon 9 duplications are associated with an
aggressive disease course [30, 77–83]. It has also been
proposed that genomic complexity, defined by a genomic
index determined by array comparative genomic hybrid-
ization, may serve as a useful adjunct to the current risk
stratification systems, which are often uninformative in the
case of intermediate-risk patients [84, 85].
It is worth noting that the updated FDA and EMA
approvals for 36 months of imatinib treatment apply to
patients who specifically meet the inclusion criteria deter-
mined in the SSGXVIII/AIO trial [7, 65]. In that trial,
imatinib treatment was initiated within the first 12 weeks
after primary surgery. Patients were eligible for the trial if
they had KIT-positive GISTs and demonstrated at least one
of the following features: longest tumor diameter[10 cm,
mitotic index[10/50 HPFs, longest tumor diameter[5 cm
and mitotic index[5/50 HPFs, or tumor rupture prior to or
at the time of surgery. This classification represents a
modified NIH risk-stratification system, complemented
with tumor rupture as an independent prognostic factor
[75]. Tumor location was excluded from the risk assess-
ment criteria in this study. Gastric GISTs constituted
approximately half of the cases in both the 12- and
36-month arms, followed by small-intestine GISTs (37 and
31 % of cases, respectively), and GISTs located in the
colon or rectum constituted 8 and 10 % of cases, respec-
tively. In 7 % of patients in each arm, the tumor was in
another location or the location was unspecified.
6 Benefit of and Resistance to Adjuvant Imatinib
Therapy
The results of the SSGXVIII/AIO trial [65] demonstrated
that mutational analysis of GISTs may have predictive
value for the clinical response to adjuvant imatinib therapy,
similar to data observed in the metastatic setting. From the
molecular point of view, resistance to imatinib has its
origins in KIT/PDGFRA mutational status. Data reported
by Joensuu and colleagues [65] showed that patients with
KIT exon 11 mutations benefit the most from prolonged
adjuvant treatment. Similar data were shown for patients
treated in the ACOSOG Z9001 trial [86]; the 2-year RFS
rate was 91 % for patients treated with adjuvant imatinib
Table 3 National Comprehensive Cancer Network (NCCN)–Armed Forces Institute of Pathology (AFIP) risk criteria after resection of primary
gastrointestinal stromal tumors (GISTs), according to Miettinen and Lasota [9]
Tumor parameters Primary tumor location and risk of recurrence
Size Mitotic index Stomach Duodenum Small intestine Rectum
B2 cm B5/50 HPFs 0 % 0 % 0 % 0 %
[2 cm, B5 cm Very low (1.9 %) Low (8.3 %) Low (4.3 %) Low (8.5 %)
[5 cm, B10 cm Low (3.6 %) High (34 %) Intermediate (24 %) High (57 %)
[10 cm Intermediate (12 %) High (52 %)
B2 cm [5/50 HPFs Insufficient data Insufficient data High (50 %) High (52–71 %)
[2 cm, B5 cm Intermediate (16 %) High (50–86 %) High (73–90 %)
[5 cm, B10 cm High (55–86 %)
[10 cm
HPFs high-powered fields




























Fig. 1 Recurrence-free survival in small-bowel gastrointestinal stro-
mal tumors (GISTs), according to National Comprehensive Cancer
Network (NCCN)–Armed Forces Institute of Pathology (AFIP) risk
categories (based on the authors’ own data from 659 primary GISTs
after radical resection, presented during the European Society of
Surgical Oncology conference [100])
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harboring KIT exon 11 mutations, as compared with 65 %
in a group of patients with the same genotype receiving
placebo (p \ 0.0001).
On the other hand, primary imatinib resistance in the
adjuvant setting has been demonstrated especially in cases
carrying a PDGFRA exon 18 p.D842V mutation, presum-
ably because of the structural alterations at the imatinib
binding site. This mutation is detected in approximately
10 % of operable GISTs [75, 87], especially in tumors
originating from the stomach (exceeding 20 % of cases in
this location) [30]. Adjuvant imatinib should not be rec-
ommended in cases of GISTs harboring a PDGFRA exon
18 p.D842V mutation. In the ACOSOG Z9001 trial [86],
adjuvant imatinib therapy had no positive impact on RFS in
this subgroup of patients.
Interestingly, it has been demonstrated that patients with
advanced GISTs harboring mutations in KIT exon 9 may
benefit from an imatinib dose increase to 800 mg daily [62].
This indicates that patients with this mutation may be
underdosed when receiving 400 mg of imatinib daily, but it
has never been examined in any clinical trial in the adjuvant
setting. In wild-type GISTs, the tumor size and mitotic index
poorly predict clinical outcome; therefore, current risk strat-
ification systems seem to be inapplicable in this subgroup of
patients [50, 51]. Moreover, wild-type GISTs present a lim-
ited response to imatinib treatment, in comparison with GISTs
carrying imatinib-sensitive mutations. Adjuvant imatinib
efficacy in KIT exon 9 mutants and wild-type GISTs warrants
further study; however, the numbers of patients in these
subgroups are usually small, and so statistical significance is
difficult to reach when these categories are analyzed [86].
Nevertheless, KIT and PDGFRA genotyping in GISTs should
be performed routinely in the adjuvant setting, since it may
help to tailor the treatment to patients who are more likely to
respond to imatinib therapy, or to exclude patients with
imatinib-resistance mutations [86, 88].
In the SSGXVIII/AIO trial, patients were monitored for
their response to imatinib with contrast-enhanced computed
tomography or magnetic resonance imaging at 6-month
intervals for the first 7 years and annually thereafter. An
initial staging examination was performed within 28 days
before the introduction of imatinib treatment. Blood bio-
chemistry and cell counts were performed at 1- to 3-month
intervals in the course of the treatment [65]. GIST relapse is
usually observed at the highest frequency within the first
2 years after completion of adjuvant treatment; therefore,
regular imaging in this period is especially important for
early detection of recurrence [64, 76]. The majority of
patients who develop GIST recurrence after completion of
adjuvant imatinib respond to an imatinib rechallenge
regardless of the prior treatment duration [64]. On the basis
of the clinical behavior of advanced GISTs, it may be
anticipated that in patients who relapse during adjuvant
treatment or within the first few weeks after completion of
adjuvant treatment, an increased dose of imatinib or intro-
duction of another tyrosine kinase inhibitor, such as suni-
tinib, may be beneficial because these cases are probably
primarily imatinib resistant. However, no clinical trial has
addressed this hypothesis as yet [64]. Generally, only a few
patients in the SSGXVIII/AIO trial developed GIST
recurrence during imatinib treatment (2 % of patients in the
12-month arm and 6 % of patients in the 36-month arm).
This suggests that acquired resistance to adjuvant imatinib
(related mainly to occurrence of secondary KIT/PDGFRA
mutations) is infrequent in this patient population [7, 65].
The optimal duration of imatinib therapy is not yet
known. We still do not know if adjuvant imatinib therapy
can cure a patient by preventing relapse or can only delay it.
In the metastatic setting, interruption of imatinib therapy
has been associated with disease relapse at a median of
6 months after stopping imatinib after 1, 3, or 5 years of
treatment [89, 90]. The significant improvement in OS
associated with 3 years versus 1 year of adjuvant imatinib
in the SSGXVIII/AIO trial [7, 65] was based on the limited
number of deaths that occurred at median follow-up of
54 months, and so longer follow-up is needed to confirm the
OS advantage related to 3-year adjuvant imatinib therapy.
7 Future of Adjuvant Imatinib Therapy
There are still several unresolved issues concerning future
use of adjuvant imatinib in GISTs. In the coming years,
adjuvant imatinib treatment for at least 3 years will be
standard therapy in high-risk GIST patients harboring
sensitive mutations. In intermediate-risk patients, adjuvant
imatinib should be considered, provided there is better
characterization of individual prognostic features. The role
of adjuvant imatinib therapy in patients with wild-type
GISTs or KIT exon 9 mutations should be better defined,
and the appropriate initial dose of imatinib—400 or
800 mg daily in patients with KIT exon 9 mutants—must
be established. The optimal duration of adjuvant imatinib
therapy beyond 3 years requires further investigation and
should preferably be determined on the basis of random-
ized controlled trials. Furthermore, the optimal follow-up
schedule after discontinuation of the therapy is not well
established. The only issue that seems to be incontestable
in the immediate future is the necessity for genotyping of
every primary GIST considered for adjuvant therapy [91].
8 Conclusions
Despite the striking efficacy of imatinib, recurrent or
metastatic GIST is still not a curable disease. This implies
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that prevention of disease recurrence following surgical
resection of the primary tumor is the key to further
improvement of the clinical outcomes of patients affected
by GISTs. Three years of adjuvant imatinib treatment, as
opposed to 1 year of treatment, significantly reduced the
risk of recurrence and improved OS in patients with KIT-
positive GISTs at high risk of recurrence after surgery [7].
Currently, 3 years of adjuvant treatment for patients at high
risk of recurrence may be considered as a standard of care.
However, it is not clear whether patients who are classified
as intermediate risk should be treated with adjuvant
imatinib. Results from several phase II studies support the
idea that at least 2 years of adjuvant imatinib treatment is
beneficial for intermediate-risk GISTs (especially those
harboring KIT exon 11 mutations) and may be considered
in this subgroup of patients [92–97]. On the other hand,
patients with very low-risk or low-risk tumors are likely to
be cured by surgery alone and should not receive adjuvant
imatinib.
Beyond risk assessment for proper selection of patients
for adjuvant imatinib therapy, mutational status also has a
predictive value for clinical response to the therapy. It may
help to tailor the treatment to patients carrying more sen-
sitive mutations, such as KIT exon 11 mutations, or to
exclude patients with imatinib-resistance mutations, such
as a PDGFRA p.D842V mutation. Thus, KIT and PDGFRA
genotyping of patients with GISTs is obligatory in the
adjuvant setting [86, 88].
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